Gabriel Mbalaviele
Pfizer Inc.
Chesterfield
MO 63017
USA
Name/email consistency: high
- Distinction of microsomal prostaglandin E synthase-1 (mPGES-1) inhibition from cyclooxygenase-2 inhibition in cells using a novel, selective mPGES-1 inhibitor. Mbalaviele, G., Pauley, A.M., Shaffer, A.F., Zweifel, B.S., Mathialagan, S., Mnich, S.J., Nemirovskiy, O.V., Carter, J., Gierse, J.K., Wang, J.L., Vazquez, M.L., Moore, W.M., Masferrer, J.L. Biochem. Pharmacol. (2010)
- A novel, highly selective, tight binding IkappaB kinase-2 (IKK-2) inhibitor: a tool to correlate IKK-2 activity to the fate and functions of the components of the nuclear factor-kappaB pathway in arthritis-relevant cells and animal models. Mbalaviele, G., Sommers, C.D., Bonar, S.L., Mathialagan, S., Schindler, J.F., Guzova, J.A., Shaffer, A.F., Melton, M.A., Christine, L.J., Tripp, C.S., Chiang, P.C., Thompson, D.C., Hu, Y., Kishore, N. J. Pharmacol. Exp. Ther. (2009)
- Inhibition of p38 mitogen-activated protein kinase prevents inflammatory bone destruction. Mbalaviele, G., Anderson, G., Jones, A., De Ciechi, P., Settle, S., Mnich, S., Thiede, M., Abu-Amer, Y., Portanova, J., Monahan, J. J. Pharmacol. Exp. Ther. (2006)
